Loading
Lung Cancer Research Studies / Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
European Heart Journal · September 7, 2026
A consensus or society position rather than new primary data.
This is a consensus Scientific Statement establishing tiered quality standards for preclinical research in cancer therapy-related cardiovascular toxicity. It identifies gaps in current practice—that experimental model selection and methods reporting are often based on personal experience rather than evidence—and proposes essential first-tier and desirable second-tier standards to improve reproducibility and rigor.
Journal article. Preclinical researchers in cardio-oncology; prospective users of quality standards for experimental design and reporting.
Preclinical research in cardio-oncology has provided biological explanation for cardiovascular adverse effects of cancer therapies, but methodology choice and reporting are frequently approximate Quality standards are distinguished into first-tier (essential for robustness) and second-tier (desirable but not necessary) categories Adherence to proposed standards is expected to benefit researchers, facilitate funding allocation, and inform development of novel oncological therapies
Preclinical research in cardio-oncology has provided biological explanation for cardiovascular adverse effects of cancer therapies, but methodology choice and reporting are frequently approximate
Clinicians and translational researchers should be aware that this statement aims to standardize preclinical research practices that underpin mechanistic understanding of cancer therapy cardiotoxicity, potentially improving the quality of evidence informing clinical decision-making in cardio-oncology. This is a quality and methodology document, not a clinical efficacy finding.
A Scientific Statement outlining quality standards and best practices for preclinical cardio-oncology research, intended to promote standardization, reproducibility, and rigor in the field.
Clinicians and translational researchers should be aware that this statement aims to standardize preclinical research practices that underpin mechanistic understanding of cancer therapy cardiotoxicity, potentially improving the quality of evidence informing clinical decision-making in cardio-oncology. This is a quality and methodology document, not a clinical efficacy finding.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Preclinical research in cancer therapy-related cardiovascular toxicity (CTR-CVT) is a major domain of cardio-oncology and has provided biological explanation for the cardiovascular adverse effects of many cancer therapies. However, the choice of the experimental models to investigate the mechanisms of CTR-CVT is often based on personal experience and opinion, rather than on established principles and available evidence. Moreover, presentation of methods and results is frequently approximate. This Scientific Statement outlines potential quality standards regarding methodology and reporting in preclinical cardio-oncology research, with the goal of promoting accurate, reliable, and reproducible studies. Quality standards are distinguished in first-tier, when considered essential for robustness unless there is a strong justification for their omission, and second-tier standards, when desirable, but not necessary. First-tier standards ensure credible, self-sustaining research, while second-tier ones enhance quality of investigations and accelerate understanding of CTR-CVT. Adherence to the proposed quality standards is expected to benefit researchers embarking on new investigations, facilitate funding allocation, and inform the development of novel oncological therapies, eventually moving cardio-oncology science forward.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.